Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care

INTRODUCTION: Since July 2021, a worldwide shortage of verteporfin (Visudyne®) occurred: an essential medicine required for photodynamic therapy (PDT). PDT with verteporfin has a broad range of indications in ophthalmology, including chronic central serous chorioretinopathy, polypoidal choroidal vas...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirks, Marc J., van Dijk, Elon H.C., Rosenberg, Noa, Hollak, Carla E.M., Aslanis, Stamatios, Cheung, Chui Ming Gemmy, Chowers, Itay, Eandi, Chiara M., Freund, K. Bailey, Holz, Frank G., Kaiser, Peter K., Lotery, Andrew J., Ohno‐Matsui, Kyoko, Querques, Giuseppe, Subhi, Yousif, Tadayoni, Ramin, Wykoff, Charles C., Zur, Dinah, Diederen, Roselie M.H., Boon, Camiel J.F., Schlingemann, Reinier O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790583/
https://www.ncbi.nlm.nih.gov/pubmed/35388619
http://dx.doi.org/10.1111/aos.15148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790583/
https://www.ncbi.nlm.nih.gov/pubmed/35388619
http://dx.doi.org/10.1111/aos.15148

Ejemplares similares